Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsBIANCO, Roberto; INCHEOL SHIN; RITTER, Christoph A et al.Oncogene (Basingstoke). 2003, Vol 22, Num 18, pp 2812-2822, issn 0950-9232, 11 p.Article

Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cellsLANXI SONG; TURKSON, James; KARRAS, James G et al.Oncogene (Basingstoke). 2003, Vol 22, Num 27, pp 4150-4165, issn 0950-9232, 16 p.Article

Involvement of spinal tyrosine kinase in inflammatory and N-methyl-D-aspartate-induced hyperalgesia in ratsSATO, Eiru; TAKANO, Yoshito; KUNO, Yuichiro et al.European journal of pharmacology. 2003, Vol 468, Num 3, pp 191-198, issn 0014-2999, 8 p.Article

Third-Generation Tyrosine Kinase Inhibitors and BeyondQUINTAS-CARDAMA, Alfonso; KANTARJIAN, Hagop; CORTES, Jorge et al.Seminars in hematology. 2010, Vol 47, Num 4, pp 371-380, issn 0037-1963, 10 p.Article

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesLOVLY, Christine M; SHAW, Alice T.Clinical cancer research (Print). 2014, Vol 20, Num 9, pp 2249-2256, issn 1078-0432, 8 p.Article

Nilotinib: A Novel, Selective Tyrosine Kinase InhibitorBLAY, Jean-Yves; VON MEHREN, Margaret.Seminars in oncology. 2011, Vol 38, Num 2, issn 0093-7754, S3-S9, SUP1Article

NilotinibDEININGER, Michael W.Clinical cancer research. 2008, Vol 14, Num 13, pp 4027-4031, issn 1078-0432, 5 p.Article

Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumorsOCHS, Judith S.International journal of radiation oncology, biology, physics. 2004, Vol 58, Num 3, pp 941-949, issn 0360-3016, 9 p.Conference Paper

Tyrosine kinase inhibitor STI-571/gleevec down-regulates the β-catenin signaling activityLAN ZHOU; AN, Naili; JAE YOON PARKA et al.Cancer letters. 2003, Vol 193, Num 2, pp 161-170, issn 0304-3835, 10 p.Article

Morphological and Hydrodynamic Correlations with Increasing Outflow Facility by Rho-Kinase Inhibitor Y-27632HAIYAN GONG; YANG, Chen-Yuan Charlie.Journal of ocular pharmacology and therapeutics. 2014, Vol 30, Num 2-3, pp 143-153, issn 1080-7683, 11 p.Conference Paper

Inhibition of Kv4.3 by genistein via a tyrosine phosphorylation-independent mechanismHEE JAE KIM; HYE SOOK AHN; BOK HEE CHOI et al.American journal of physiology. Cell physiology. 2011, Vol 69, Num 3, issn 0363-6143, C567-C575Article

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107VON BUBNOFF, N; GORANTLA, S. H. P; KANCHA, R. K et al.Leukemia. 2005, Vol 19, Num 9, pp 1670-1671, issn 0887-6924, 2 p.Article

Kinase drug discovery approaches in chronic myeloproliferative disordersKUMAR, C; PURANDARE, A. V; LEE, F. Y et al.Oncogene (Basingstoke). 2009, Vol 28, Num 24, pp 2305-2313, issn 0950-9232, 9 p.Article

Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapySMITH, John K; MAMOON, Naila M; DUHE, Roy J et al.Oncology research. 2004, Vol 14, Num 4-5, pp 175-225, issn 0965-0407, 51 p.Article

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumorsMURAKAMI, Haruyasu; UEDA, Yutaka; SHIMOYAMA, Tatsu et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 5, pp 1119-1128, issn 0344-5704, 10 p.Article

Tyrosine kinase inhibitor loaded PCL microspheres prepared by S/O/W technique using ethanol as pretreatment agentYANTING ZHANG; YAQIONG ZHANG; SHENGRONG GUO et al.International journal of pharmaceutics (Print). 2009, Vol 369, Num 1-2, pp 19-23, issn 0378-5173, 5 p.Article

Diagnosis and treatment of hypereosinophilic syndromesFLETCHER, Sarah; BAIN, Barbara.Current opinion in hematology. 2007, Vol 14, Num 1, pp 37-42, issn 1065-6251, 6 p.Article

Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitorROUTHOUSKA, Shannon; GILLIAM, Anita C; MIRMIRANI, Paradi et al.Archives of dermatology (1960). 2006, Vol 142, Num 11, pp 1477-1479, issn 0003-987X, 3 p.Article

Immunomodulatory effects of anti-angiogenic drugsHEINE, A; HELD, Sae; BRINGMANN, A et al.Leukemia. 2011, Vol 25, Num 6, pp 899-905, issn 0887-6924, 7 p.Article

Systemic therapy in neurofibromatosis type 2LIM, Stephanie Hui-Su; ARDERN-HOLMES, Simone; MCCOWAGE, Geoffrey et al.Cancer treatment reviews. 2014, Vol 40, Num 7, pp 857-861, issn 0305-7372, 5 p.Article

Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosisCAPONETTI, Gabriel C; MIRANDA, Roberto N; ALTHOF, Pamela A et al.Human pathology. 2012, Vol 43, Num 12, pp 2223-2228, issn 0046-8177, 6 p.Article

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaMILOJKOVIC, Dragana; NICHOLSON, Emma; KHORASHAD, Jamshid S et al.Haematologica (Roma). 2010, Vol 95, Num 2, pp 224-231, issn 0390-6078, 8 p.Article

Current treatment strategies in chronic myeloid leukemiaGUILHOT, François; ROY, Lydia; TOMOWIAK, Cécile et al.Current opinion in hematology. 2012, Vol 19, Num 2, pp 102-109, issn 1065-6251, 8 p.Article

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumorsUEDA, Yutaka; SHIMOYAMA, Tatsu; MURAKAMI, Haruyasu et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 5, pp 1101-1109, issn 0344-5704, 9 p.Article

Hematologic toxicities of small molecule tyrosine kinase inhibitors : TARGETED THERAPY TOXICITIESBARBER, Nicholas A; AFZAL, Wais; AKHTARI, Mojtaba et al.Targeted oncology. 2011, Vol 6, Num 4, pp 203-215, issn 1776-2596, 13 p.Article